Evidence-Based Complementary and Alternative Medicine / 2020 / Article / Tab 2

Research Article

Network Pharmacology Identifies the Mechanisms of Sang-Xing-Zhi-Ke-Fang against Pharyngitis

Table 2

Functions of 387 target genes based on KEGG pathway analysis.

TermNumber of pathway gene value

Linoleic acid metabolismCYP3A4, CYP2J2, CYP2C19, CYP2C9, CYP2C8, CYP2E1, CYP1A2, PLA2G4A, PLA2G1B, PLA2G2A, PLA2G6, PLA2G3, PLA2G4C, PLA2G51.20E − 11
VEGF signaling pathwayPIK3CG, PRKCA, PTGS2, MAPKAPK2, PRKCB, PLA2G4A, KRAS, RAC2, MAPK14, MAPK3, RAC1, PLA2G4C, AKT22.69E − 06
Serotonergic synapsePRKCA, PLA2G4A, APP, CYP2J2, KRAS, CYP2C19, PTGS2, CYP2C9, CYP2C8, CYP2D6, MAPK3, PTGS1, ALOX12B, PRKACA, ALOX5, PLA2G4C, PRKCB4.54E − 06
Fc epsilon RI signaling pathwayIL4, PIK3CG, PRKCA, PRKCB, PLA2G4A, KRAS, RAC2, MAPK14, MAPK3, RAC1, PLA2G4C, SYK, AKT28.83E − 06
Alpha-linolenic acid metabolismACOX1, PLA2G4A, PLA2G2A, PLA2G1B, PLA2G6, PLA2G4C, PLA2G3, PLA2G53.08E − 05
Pancreatic cancerPIK3CG, KRAS, RAC2, TGFBR1, MAPK3, TGFBR2, RAC1, NFKB1, SMAD2, EGF, TGFB1, AKT23.17E − 05
Chagas disease (American trypanosomiasis)PIK3CG, CCL3, TGFBR1, TGFBR2, NFKBIA, NFKB1, SMAD2, BDKRB2, CALR, TGFB1, ACE, MAPK14, MAPK3, FAS, AKT23.98E − 05
Metabolism of xenobiotics by cytochrome P450CYP3A4, CYP2A13, CYP3A5, CYP1B1, CYP1A1, CYP2B6, CYP2C9, CYP2D6, CYP2A6, CYP2E1, CYP1A2, AKR1C11.09E − 04
Sphingolipid signaling pathwayPRKCA, PIK3CG, SGMS2, CERS5, NFKB1, SGMS1, BDKRB2, PRKCB, KRAS, RAC2, MAPK14, MAPK3, RAC1, ABCC1, AKT21.93E − 04
Chemical carcinogenesisCYP3A4, CYP2A13, CYP3A5, CYP1B1, CYP1A1, CYP2C19, PTGS2, CYP2C9, CYP2C8, CYP2A6, CYP2E1, CYP1A22.22E − 04
Ras signaling pathwayPRKCA, PIK3CG, FGFR4, CSF1, NFKB1, PRKCB, PLA2G4A, KRAS, RAC2, RAC1, MAPK3, PLA2G1B, PLA2G2A, PLA2G6, PRKACA, FGF1, PLA2G3, PLA2G4C, EGF, PLA2G5, AKT24.17E − 04
Osteoclast differentiationPIK3CG, NCF2, TGFBR1, CSF1, CREB1, PPARG (PPARP), TGFBR2, NFKBIA, NFKB1, TGFB1, MAPK14, MAPK3, RAC1, AKT2, SYK4.83E − 04
Colorectal cancerPIK3CG, KRAS, RAC2, TGFBR1, MAPK3, TGFBR2, RAC1, SMAD2, TGFB1, AKT25.51E − 04
FoxO signaling pathwayPIK3CG, TGFBR1, TGFBR2, SMAD2, SIRT1, TGFB1, G6PC, KRAS, MAPK14, MAPK3, PRKAA1, CAT, PRKAA2, EGF, AKT26.08E − 04
Retinol metabolismCYP3A4, CYP3A5, DGAT1, CYP1A1, CYP2B6, CYP2C9, CYP2C8, HSD17B6, CYP2A6, CYP1A27.00E − 04
MAPK signaling pathwayPRKCA, FGFR4, TGFBR1, TGFBR2, NFKB1, HSPA1A, HSPA1B, MAPKAPK2, TGFB1, PRKCB, PLA2G4A, KRAS, RAC2, MAPK14, RAC1, MAPK3, PRKACA, FAS, FGF1, PLA2G4C, EGF, AKT27.04E − 04
Drug metabolism-cytochrome P450CYP3A4, CYP3A5, CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP2D6, CYP2A6, CYP2E1, CYP1A20.001095
B Cell receptor signaling pathwayPIK3CG, KRAS, RAC2, MAPK3, RAC1, CD81, NFKBIA, NFKB1, AKT2, SYK0.001218
Hepatitis CPIK3CG, PPARA, LDLR, RXRA, NFKBIA, NFKB1, KRAS, MAPK14, MAPK3, CD81, SCARB1, EGF, AKT2, NR1H30.001755
Influenza APRKCA, PIK3CG, IL18, FDPS, NFKBIA, NLRX1, HSPA1A, NFKB1, HSPA1B, NLRP3, PRKCB, MAPK14, MAPK3, PYCARD, FAS, AKT20.002805

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.